U.S. Markets closed

Catalyst Pharmaceuticals, Inc. (CPRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.72-0.05 (-1.81%)
At close: 4:00PM EDT

2.72 0.00 (0.00%)
After hours: 4:14PM EDT

People also watch
IDRACYCCCLSNTHLDATHX

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 1250
Coral Gables, FL 33134
United States
305-529-2522
http://www.catalystpharma.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees18

Key Executives

NameTitlePayExercisedAge
Mr. Patrick J. McEnanyCo-Founder, Chairman, Chief Exec. Officer and Pres496.56kN/A70
Ms. Alicia Grande CPA, CMAChief Financial Officer, Chief Accounting Officer, VP and Treasurer326.6kN/A46
Dr. Steven R. Miller Ph.D.Chief Operating Officer and Chief Scientific Officer394.2kN/A55
Dr. Gary Ingenito M.D., Ph.D.Chief Medical Officer and Head of Regulatory Affairs375.83kN/A61
Mr. Brian ElsberndSr. VP of Legal and ComplianceN/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. The company also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette’s disorder; and CPP-109 to treat Tourette’s disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.